Skip to content

CorMedix

US · CRMD #3663 by market cap
5.27 +0.19 +3.74%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 4.99 -1.77%
After-hours 5.32 +0.95%
Overnight 5.03 -0.98%
8.964.505.272026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CRMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -40.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 18.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A

The radar needs all six factors. Available grades are shown below.

Valuation B+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 8.2x Better than 87%
Price / Sales 0.9x Better than 80%
P/E vs own 5-yr range 89th pctl Better than 15%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 88.5% Better than 96%
Operating margin 48.2% Better than 97%
Net margin 52.0% Better than 97%
Return on equity 66.2% Better than 96%
Return on invested capital 50.4% Better than 99%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -35.7% Better than 13%
6-month return -34.0% Better than 15%
12-month return (ex latest month) -18.9% Better than 16%
Distance below 52-week high 59.5% Better than 11%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.1x Better than 58%
Debt to assets 18.0% Better than 58%
Interest coverage 54.9x Better than 90%
Free cash flow / net income 106.0% Better than 42%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 165.7% Better than 91%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +13.09%
1M -30.38%
3M -35.97%
6M -33.54%
YTD -54.69%
1Y -45.78%
3Y +39.42%
5Y +2.73%

Key statistics

Price & volume

Prev close
5.08
Open
4.96
Day range
4.95 - 5.32
Avg price
5.18
Volume
3.61M
Turnover
18.70M
Amplitude
7.19%
52-week range
4.47 - 13.02

Valuation

P/E
2.58
P/E (TTM)
8.23
P/B
0.91
EPS
2.04
Net profit
162.26M
Net assets
461.72M

Share structure

Market cap
419.16M
Float cap
355.21M
Shares out
79.54M
Float shares
67.40M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 9% of range
4.47 13.02

59.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.79M net over the window

Short interest

Shares short
14.21M
As of
2026-10-30

Frequently asked questions

What is the current stock price of CorMedix (CRMD)?

CorMedix last traded at 5.27. This page shows a periodic quote snapshot. Check the displayed quote time.

What is CorMedix's market cap?

About 419.16M.

What is the P/E ratio of CorMedix?

The trailing twelve-month P/E is 8.23. The Valuation tab shows it against the stock's own five-year range.

Does CorMedix pay a dividend?

CorMedix does not currently pay a regular dividend.

Is CorMedix a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 14.00, which implies 165.7% upside from the current price. This is not investment advice.

What is CorMedix's StockVane Quant Rating?

The StockVane Momentum strategy currently rates CorMedix a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

CorMedix discussion 0 comments

Add a comment